Blood product, a method of producing the same and a method of determining the virus inactivation capacity of an inactivation treatment
CA 2071567 C · Owner: Eibl, Johann · Inventors: Linnau, Yendra; Wober, Guenther; Eibl, Johann
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a blood product exclusive of, albumin, inactivated relative to infectious agents the, blood product conforming to a total virus reduction factor of at least 40, having a biologic acitity of at least 50%, based on its activity prior to effecting inactivation of the infectious agents. The blood product according to the invention may be produced from conventional blood products and is virus-safe.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 18, 1992 and granted April 29, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 18, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 18, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.